Day One Biopharmaceuticals, Inc.

  • Moat Score
  • Market Cap $654.97M
  • PE -7
  • Debt -
  • Cash $124.97M
  • EV -
  • FCF -$80.28M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$95.50M
EBIT-$217.27M
ROE-19%
ROA-37%
FCF-$80.28M
Equity$502.75M
Growth Stability1
PE-6.86
PB1.3
P/FCF-8.16
P/S4.99
Price/Cash0.19
Net Margins-73%
Op. Margins-166%
Equity CAGR11%
Earnings Growth YoY21%
Earnings Growth QoQ-277%
Equity CAGR 5Y12%
Equity CAGR 3Y13%
Market Cap$654.97M
Revenue$131.16M
Assets$582.79M
Cash$124.97M
Shares Outstanding93.23M
Moat Score2%
Working Capital488.88M
Current Ratio7.66
Shares Growth 3y20%
Equity Growth QoQ-9%
Equity Growth YoY45%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

SEC Filings

Direct access to Day One Biopharmaceuticals, Inc. (DAWN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Day One Biopharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Day One Biopharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Day One Biopharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Day One Biopharmaceuticals, Inc..

= -$803M
012345678910TV
fcf-$80M-$80M-$80M-$80M-$80M-$80M-$80M-$80M-$80M-$80M-$80M-$803M
DCF-$73M-$66M-$60M-$55M-$50M-$45M-$41M-$37M-$34M-$31M-$310M
Value-$803M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201912/202012/202112/202212/202312/2024TTM
Net Margins------73%-73%
ROA--30%-25%-42%-55%-37%-37%
ROE-81%-26%-43%-55%-19%-19%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-------
Debt over Equity-------
Growth Stability------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-------
Earnings YoY growth-158%66%95%33%-49%-
Equity YoY growth-408%-619%18%4%45%12%
FCF YoY growth-201%257%126%34%-45%-